| Literature DB >> 27292188 |
Maria Anna Zipeto1, Angela C Court1, Anil Sadarangani1, Nathaniel P Delos Santos1, Larisa Balaian1, Hye-Jung Chun2, Gabriel Pineda1, Sheldon R Morris1, Cayla N Mason1, Ifat Geron1, Christian Barrett3, Daniel J Goff1, Russell Wall1, Maurizio Pellecchia4, Mark Minden5, Kelly A Frazer3, Marco A Marra2, Leslie A Crews1, Qingfei Jiang6, Catriona H M Jamieson7.
Abstract
Post-transcriptional adenosine-to-inosine RNA editing mediated by adenosine deaminase acting on RNA1 (ADAR1) promotes cancer progression and therapeutic resistance. However, ADAR1 editase-dependent mechanisms governing leukemia stem cell (LSC) generation have not been elucidated. In blast crisis chronic myeloid leukemia (BC CML), we show that increased JAK2 signaling and BCR-ABL1 amplification activate ADAR1. In a humanized BC CML mouse model, combined JAK2 and BCR-ABL1 inhibition prevents LSC self-renewal commensurate with ADAR1 downregulation. Lentiviral ADAR1 wild-type, but not an editing-defective ADAR1(E912A) mutant, induces self-renewal gene expression and impairs biogenesis of stem cell regulatory let-7 microRNAs. Combined RNA sequencing, qRT-PCR, CLIP-ADAR1, and pri-let-7 mutagenesis data suggest that ADAR1 promotes LSC generation via let-7 pri-microRNA editing and LIN28B upregulation. A small-molecule tool compound antagonizes ADAR1's effect on LSC self-renewal in stromal co-cultures and restores let-7 biogenesis. Thus, ADAR1 activation represents a unique therapeutic vulnerability in LSCs with active JAK2 signaling.Entities:
Mesh:
Substances:
Year: 2016 PMID: 27292188 PMCID: PMC4975616 DOI: 10.1016/j.stem.2016.05.004
Source DB: PubMed Journal: Cell Stem Cell ISSN: 1875-9777 Impact factor: 24.633